Radiolabeled iron oxide nanoparticles as dual-modality SPECT/MRI and PET/MRI agents

Curr Top Med Chem. 2012;12(23):2694-702. doi: 10.2174/1568026611212230007.

Abstract

Dual-modality contrast agents, such as radiolabeled nanoparticles, are promising candidates for a number of diagnostic applications, since they combine the advantages of two different imaging modalities, namely SPECT or PET imaging with MR imaging. The benefit of such a combination is to more accurately interpret disease and abnormalities in vivo, by exploiting the advantages of each imaging technique, i.e. high sensitivity for SPECT/PET, high resolution anatomical information for MRI. In this review article, we provide an overview of recent findings in the synthesis, evaluation and application of radiolabeled iron oxide nanoparticles as dual-modality SPECT/MRI and PET/MRI imaging probes.

Publication types

  • Review

MeSH terms

  • Antibodies / chemistry
  • Antineoplastic Agents / chemistry
  • Contrast Media* / chemistry
  • Contrast Media* / therapeutic use
  • Ferric Compounds* / chemistry
  • Humans
  • Isotope Labeling
  • Magnetic Resonance Imaging / instrumentation
  • Magnetic Resonance Imaging / methods
  • Magnetite Nanoparticles* / chemistry
  • Magnetite Nanoparticles* / therapeutic use
  • Neoplasms / diagnosis*
  • Neoplasms / diagnostic imaging
  • Neoplasms / radiotherapy*
  • Peptides / chemistry
  • Positron-Emission Tomography / instrumentation
  • Positron-Emission Tomography / methods
  • Radioisotopes / chemistry
  • Tomography, Emission-Computed, Single-Photon / instrumentation
  • Tomography, Emission-Computed, Single-Photon / methods

Substances

  • Antibodies
  • Antineoplastic Agents
  • Contrast Media
  • Ferric Compounds
  • Magnetite Nanoparticles
  • Peptides
  • Radioisotopes
  • ferric oxide